Department of Biological Sciences
National University of Singapore
Science Drive 4,
PhD, Goteborg, SWEDEN; BSc, Fudan, PRC
Immune cell therapy against cancer
Current Research Interests
Immunotherapies selectively activate the immune system in patients and have sparked a revolution in cancer treatment. The research focus of my laboratory is on the development of biological therapy approaches applicable to cancer immunotherapy. In recent several years, we have been working towards building platform technologies that support the development of novel immune cell-based therapeutics. Powerful cell generation, expansion, and modification technologies used in the production process for cancer immunotherapy have been established. Several new cellular therapeutics in the area of chimeric antigen receptor (CAR) adoptive immunotherapy and with potential for use against a broad range of cancers are under testing currently. We aim to make a contribution to the progress of translational medicine, translating discoveries in basic immunology into safe and effective therapeutic applications.
Selected Recent Publications
Ng YY, Tay JCK, Li Z, Wang J, Zhu J, Wang S. T Cells Expressing NKG2D CAR with a DAP12Signaling Domain Stimulate Lower Cytokine Production while Effective in Tumor Eradication. Molecular Therapy. 2020 Sep 5; S1525-0016(20)30426-3.
Li Z, Chi Z, Ang WX, Chen C, Tay JC, Ng YY, Xu X, Wang J, Zhu J, Wang S. Experimental treatment of colorectal cancer in mice with human T cells electroporated with NKG2D RNA CAR. Immunotherapy. 2020 Jul;12(10):733-748
Ang WX, Ng YY, Xiao L, Chen C, Li Z, Chi Z, Tay JC, Tan WK, Zeng J, Toh HC, Wang S. Electroporation of NKG2D RNA CAR Improves Vγ9Vδ2 T Cell Responses against Human Solid Tumor Xenografts. Molecular Therapy Oncolytics. 2020 May 4; 17:421-430.
Ng YY, Tay JCK, Wang S. CXCR1 Expression to Improve Anti-Cancer Efficacy of Intravenously Injected CAR-NK Cells in Mice with Peritoneal Xenografts. Molecular Therapy Oncolytics. 2019 Dec 24; 16:75-85.
Zha S, Li Z, Chen C, Du Z, Tay JC, Wang S. Beta-2 microglobulin knockout K562 cell-based artificial antigen presenting cells for ex vivo expansion of T lymphocytes. Immunotherapy. 2019 Aug; 11(11):967-982.
Zeng J, Tang SY, Wang S. Derivation of mimetic γδ T cells endowed with cancer recognition receptors from reprogrammed γδ T cell. PLoS One. 2019 May 9; 14(5):e0216815.
Tan WK, Tay JCK, Zeng J, Zheng M, Wang S. Expansion of Gamma Delta T Cells – A Short Review on Bisphosphonate and K562-Based Methods. J Immunological Sci. (2018); 2(3): 6-12
Xiao L, Chen C, Li Z, Zhu S, Tay JC, Zhang X, Zha S, Zeng J, Tan WK, Liu X, Chng WJ, Wang S. Large-scale expansion of Vγ9Vδ2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells. Cytotherapy. 2018 Mar; 20(3):420-435.
Tay JC, Zha S, Wang S. Chimeric switch receptor: switching for improved adoptive T-cell therapy against cancers. Immunotherapy. 2017 Dec; 9(16):1339-1349.
Zeng J, Tang SY, Toh LL, Wang S. Generation of “Off-the-Shelf” Natural Killer Cells from Peripheral Blood Cell-Derived Induced Pluripotent Stem Cells. Stem Cell Reports. 2017 Dec 12; 9(6):1796-1812.
Ang WX, Li Z, Chi Z, Du SH, Chen C, Tay JC, Toh HC, Connolly JE, Xu XH, Wang S. Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis. Oncotarget. 2017 Feb 21; 8(8):13545-13559.
Du SH, Li Z, Chen C, Tan WK, Chi Z, Kwang TW, Xu XH, Wang S. Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy. PLoS One. 2016 Sep 6; 11(9): e0161820.